There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), AnaptysBio (ANAB – Research Report) and US Physical Therapy (USPH – Research Report) with bullish sentiments.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Keros Therapeutics (KROS)
Leerink Partners analyst Thomas Smith maintained a Buy rating on Keros Therapeutics on December 13 and set a price target of $35.00. The company’s shares closed last Friday at $18.83, close to its 52-week low of $15.67.
According to TipRanks.com, Smith is a top 100 analyst with an average return of 42.6% and a 54.1% success rate. Smith covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Keros Therapeutics with a $64.89 average price target, a 245.9% upside from current levels. In a report issued on December 3, Wells Fargo also maintained a Buy rating on the stock with a $88.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
AnaptysBio (ANAB)
In a report issued on December 12, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio, with a price target of $32.00. The company’s shares closed last Friday at $15.59, close to its 52-week low of $14.20.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of 14.4% and a 58.2% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals.
AnaptysBio has an analyst consensus of Moderate Buy, with a price target consensus of $43.90, representing a 197.4% upside. In a report issued on December 11, TD Cowen also maintained a Buy rating on the stock with a price target.
US Physical Therapy (USPH)
US Physical Therapy received a Buy rating and a $113.00 price target from JMP Securities analyst Constantine Davides today. The company’s shares closed last Friday at $93.46.
According to TipRanks.com, Davides ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.0% and a 22.4% success rate. Davides covers the Healthcare sector, focusing on stocks such as Cross Country Healthcare, AMN Healthcare Services, and Privia Health Group.
US Physical Therapy has an analyst consensus of Moderate Buy, with a price target consensus of $110.25, which is a 17.8% upside from current levels. In a report issued on December 3, J.P. Morgan also maintained a Buy rating on the stock with a $120.00 price target.
Read More on KROS: